Journal Mobile Options
Table of Contents
Vol. 76, No. 3, 2009
Issue release date: March 2009
Oncology 2009;76:212–219

Stereotactic Body Radiation Therapy Using Three Fractions for Isolated Lung Recurrence from Colorectal Cancer

Kim M.-S. · Yoo S.Y. · Cho C.K. · Yoo H.J. · Choi C.W. · Seo Y.S. · Kang J.K. · Lee D.H. · Hwang D.Y. · Moon S.M. · Kim M.S. · Kang H.J. · Kim Y.H.
aDepartment of Radiation Oncology, bCyberKnife Center, and Departments of cGeneral Sugery, dPathology, eHemato-Oncology and fRadiology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To determine the feasibility of stereotactic body radiotherapy (SBRT) using 3 fractions for isolated colorectal lung metastases. Methods: From June 2003 to December 2006, 13 cases of isolated pulmonary metastasis from colorectal cancer were treated by SBRT due to an inoperable state (7 patients), or the patient’s refusal to undergo surgical excision (6 patients). All patients underwent chemotherapy for salvage treatment. SBRT doses ranged from 39 to 51 Gy in 3 fractions. Nine patients had a solitary lesion, 3 patients had 2 lesions, and 1 patient had 3 lesions. Median tumor volume for the 18 lesions was 5.9 ml (range 1.6–45 ml). Results: Follow-up duration was 15–57 months. Three-year overall survival, local control and progression-free survival rates were 64.7, 52.7 and 11.5%, respectively.Univariate analysis showed that total internal target volume was a significant prognostic factor for local control. During the follow-up, 11 of the 13 patients experienced local recurrence, distant metastasis or both. The most frequent site of failure was in a nontargeted lung region. No severe complication was attributed to SBRT. Conclusion: Our study suggests the potential feasibility of SBRT for selected patients with 1–3 small metastatic nodules. A further larger-scale study is required to define the indications for SBRT in cases with isolated pulmonary metastasis from colorectal cancer.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ: Lung resection for colorectal metastases: 10-year results. Arch Surg 1992;127:1403–1406.
  2. Goya T, Miyazawa N, Kondo H, Tsuchiya R, Naruke T, Suemasu K: Surgical resection of pulmonary metastases from colorectal cancer: 10-year follow-up. Cancer 1989;64:1418–1421.
  3. August DA, Ottow RT, Sugarbaker PH: Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 1984;3:303–324.
  4. Brister SJ, de Varennes B, Gordon PH, Sheiner NM, Pym J: Contemporary operative management of pulmonary metastases of colorectal origin. Dis Colon Rectum 1988;31:786–792.
  5. Sakamoto T, Tsubota N, Iwanaga K, Yuki T, Matsuoka H, Yoshimura M: Pulmonary resection for metastases from colorectal cancer. Chest 2001;119:1069–1072.
  6. Morrow CE, Vassilopoulos PP, Grage TB: Surgical resection for metastatic neoplasms of the lung: experience at the University of Minnesota Hospitals. Cancer 1980;45:2981–2985.
  7. Watanabe I, Arai T, Ono M, Sugito M, Kawashima K, Ito M, Nagai K, Saito N: Prognostic factors in resection of pulmonary metastasis from colorectal cancer. Br J Surg 2003;90:1436–1440.
  8. Pfannschmidt J, Muley T, Hoffmann H, Dienemann H: Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 2003;126:732–739.
  9. Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002;124:1007–1013.
  10. Rena O, Casadio C, Viano F, Cristofori R, Ruffini E, Filosso PL, Maggi G: Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg 2002;21:906–912.
  11. Pfannschmidt J, Dienemann H, Hoffmann H: Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007;84:324–338.
  12. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C, Gruppo Oncologico Dell’Italia Meridionale: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23:4866–4875.
  13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
  14. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059–2069.
  15. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.
  16. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–1047.
  17. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M: Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004;60:186–196.
  18. Nakagawa K, Aoki Y, Tago M, Terahara A, Ohtomo K: Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors: original research in the treatment of thoracic neoplasms. Int J Radiat Oncol Biol Phys 2000;48:449–457.
  19. Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu D, Whyte RI, Donington J: Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006;1:802–809.
  20. Kim MS, Ha S, Lee DH, Ji YH, Yoo SY, Cho CK, Yang DM, Yoo HJ, Seo YS, Park CI, Kim IH, Ye SJ, Park JH, Kim KB: Distortion of the dose profile in a three-dimensional moving phantom to simulate tumor motion during image-guided radiosurgery. J Korean Soc Ther Radiol 2007;25:268–278.
  21. Koga R, Yamamoto J, Saiura A, Yamaguchi T, Hata E, Sakamoto M: Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 2006;36:643–648.
  22. Yan TD, King J, Sjarif A, Glenn D, Steinke K, Morris DL: Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol 2006;13:1529–1537.
  23. Hiraki T, Gobara H, Iishi T, Sano Y, Iguchi T, Fujiwara H, Tajiri N, Sakurai J, Date H, Mimura H, Kanazawa S: Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: midterm results in 27 patients. J Vasc Interv Radiol 2007;18:1264–1269.
  24. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, Wong JR, Kusano S: Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666–670.
  25. Arimoto T, Usubuchi H, Matsuzawa T, et al: Small volume multiple non-coplanar arc radiotherapy for tumors of lung, head & neck and the abdominopelvic region; in Lemke HU (ed): CAR’98 Computer Assisted Radiology and Surgery. Tokyo, Elsevier, 1998, pp 257–261.
  26. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946–1955.
  27. Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H: Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003;56:126–135.
  28. Lee SW, Choi EK, Park HJ, Ahn SD, Kim JH, Kim KJ, Yoon SM, Kim YS, Yi BY: Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003;40:309–315.
  29. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427–1431.
  30. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833–4839.
  31. Higashiyama M, Kodama K, Higaki N, Takami K, Murata K, Kameyama M, Yokouchi H: Surgery for pulmonary metastases from colorectal cancer: the importance of prethoracotomy serum carcinoembryonic antigen as an indicator of prognosis. Jpn J Thorac Cardiovasc Surg 2003;51:289–296.
  32. Kanemitsu Y, Kato T, Hirai T, Yasui K: Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004;91:112–120.
  33. Welter S, Jacobs J, Krbek T, Poettgen C, Stamatis G: Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. Eur J Cardiothorac Surg 2007;31:167–172.
  34. Collins BT, Erickson K, Reichner CA, Collins SP, Gagnon GJ, Dieterich S, McRae DA, Zhang Y, Yousefi S, Levy E, Chang T, Jamis-Dow C, Banovac F, Anderson ED: Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol 2007;2:39.
  35. King J, Glenn D, Clark W, Zhao J, Steinke K, Clingan P, Morris DL: Percutaneous radiofrequency ablation of pulmonary metastases in patients with colorectal cancer. Br J Surg 2004;91:217–223.
  36. Steinke K, Sewell PE, Dupuy D, Lencioni R, Helmberger T, Kee ST, Jacob AL, Glenn DW, King J, Morris DL: Pulmonary radiofrequency ablation – an international study survey. Anticancer Res 2004;24:339–343.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50